54 results
424B3
BTTX
Better Therapeutics Inc
10 Jan 24
Prospectus supplement
7:01am
therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid
8-K
EX-99.1
BTTX
Better Therapeutics Inc
8 Jan 24
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
4:42pm
behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the management of type 2 diabetes
424B3
BTTX
Better Therapeutics Inc
28 Dec 23
Prospectus supplement
9:23pm
therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D adjunctively with standard-of-care … patients on changes in diet and exercise. Since AspyreRx offers providers a clinically proven behavioral therapy that targets behaviors around diet
8-K
EX-99.1
w0uyrn8x59hy 23
9 Nov 23
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
7:03am
424B5
nhf h7nvtefdprc1nr
9 Aug 23
Prospectus supplement for primary offering
4:37pm
8-K
EX-99.1
dhx 6tr141uoa
9 Aug 23
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:07pm
8-K
EX-99.1
ubutxtnkn gqhh
26 Jul 23
Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share
5:11pm
8-K
EX-99.1
emfls6vzy
12 Jul 23
Better Therapeutics Receives FDA Authorization for AspyreRxTM to Treat Adults with Type 2 Diabetes
12:00am